Please login to the form below

Not currently logged in

PhRMA appoints senior government affairs position

Charles Clapton has senior experience on Capitol Hill
PhRMA charles clapton

US trade body the Pharmaceutical Research and Manufacturers of America (PhRMA) has appointed Charles 'Chuck' Clapton as senior VP, federal advocacy.

Taking on the role from March 17, Clapton will be responsible for leading PhRMA's federal government affairs initiatives and advancing its legislative agenda.

This includes working with stakeholders to develop health policies that cater for PhRMA's priorities of innovation and patient access to medicines.

Clapton said: “I look forward to representing PhRMA members and assisting their efforts to help patients improve access to new treatments and support policies foster the continuing development of new treatments and cures."

He has a legal background, serving most recently at law firm HoganLovells, where he was responsible for many healthcare clients and his past experience includes senior public sector roles on the House Energy & Commerce Committee, Ways & Means Committee, Office of the Speaker and the Senate Health, Education, Labor and Pensions Committee.

During this time, he worked on Medicare and issues related to the FDA.

Chip Davis, executive VP, advocacy and member relations at PhRMA, commented: "Chuck's experience, reputation, and results-oriented focus during his distinguished career on Capitol Hill will be tremendous assets to PhRMA and its members as he leads our Federal Advocacy efforts."

3rd March 2014

From: Marketing, Regulatory, Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...